• Heartflow Holding Inc (NYSE: HFLO) aims to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a SPAC merger with Longview Acquisition Corp II (NYSE: LGV).

  • Once the deal, valued at an enterprise value of about $2.4 billion, is complete, the resulting public company will operate under HeartFlow's banner with the NYSE ticker HFLO.

  • The company offers a test that uses artificial intelligence to build an individualized map of each patient's cardiovascular anatomy and function to diagnose coronary artery disease.

  • The merger is expected to close in the fourth quarter of this year, pending customary conditions and SEC approval.

  • Longview II is backed by Glenview Capital Management, which previously merged its elder Longview Acquisition Corp with the portable ultrasound maker Butterfly Network Inc (NYSE: BFLY) in a $1.5 billion SPAC deal completed earlier this year.

  • The solution allows cardiologists to determine the severity of a coronary blockage without requiring an invasive cardiac catheterization.

  • Price Action: LGV shares are trading higher by 0.41% $9.90 in the market session on the last check Friday.

See more from Benzinga

  • Click here for options trades from Benzinga

  • Celularity Closes SPAC Merger With GX Acquisition, Trading Starts Monday

  • GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888